Maze Therapeutics, Inc. (MAZE) — Financial statements
Income statement, balance sheet, and cash flow for Maze Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue & Gross Profit | |||||
| Revenue | 0.00↓100.0% | 168 | 0.00 | 0.00 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -2↓101.4% | 168 | 0.00 | 0.00 | |
| Operating Expenses | |||||
| R&D Expenses | 108↑29.9% | 83↑12.9% | 74↓16.2% | 88 | |
| General & Administrative Expenses | 34↑30.4% | 26↑7.4% | 25↑7.8% | 23 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 34↑30.4% | 26↑7.4% | 25↑7.8% | 23 | |
| Other Expenses | -2 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 140↑27.8% | 110↑11.5% | 99↓11.2% | 111 | |
| Total Costs & Expenses | 143↑30.0% | 110↑11.5% | 99↓11.2% | 111 | |
| Operating Results | |||||
| Operating Income | -143↓348.1% | 58↑158.4% | -99↑11.2% | -111 | |
| Depreciation & Amortization | 2↓27.1% | 3↓19.4% | 4↑7.0% | 4 | |
| EBITDA | -140↓330.8% | 61↑164.5% | -94↑11.9% | -107 | |
| EBIT | -143↓348.1% | 58↑158.4% | -99↑11.2% | -111 | |
| Interest & Other Income | |||||
| Net Interest Income | 0.00↓100.0% | 5↑136.7% | 2↓3.1% | 2 | |
| Interest Income | 0.00↓100.0% | 5↑136.7% | 2↓3.1% | 2 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 12↑381.6% | -4↓124.4% | -2↑52.4% | -4 | |
| Income Before Tax | -131↓345.5% | 53↑153.2% | -100↑12.6% | -115 | |
| Income Tax Expense | 0.00↓100.0% | 1 | 0.00 | 0.00 | |
| Net Income & EPS | |||||
| Net Income from Continuing Operations | -131↓351.0% | 52↑152.0% | -100↑12.6% | -115 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -131↓351.0% | 52↑152.0% | -100↑12.6% | -115 | |
| Bottom-Line Net Income | -131↓3950.8% | 3↑103.4% | -100↑12.6% | -115 | |
| EPS (Basic) | -3.05↓4020.3% | 0.08↑103.4% | -2.29↑12.6% | -2.63 | |
| EPS (Diluted) | -3.05↓4020.3% | 0.08↑103.4% | -2.29↑12.6% | -2.63 | |
| Weighted Average Shares | 43↓1.9% | 44↑0.0% | 44↑0.0% | 44 | |
| Weighted Average Diluted Shares | 43↓1.9% | 44↑0.0% | 44↑0.0% | 44 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.